肺表面活性物质治疗新生儿肺透明膜病的临床分析  

Observing the Effect of Pulmonary Surfactant to Prevent Hyaline Membrane Disease

作　　者：江栋昌[1] 

机构地区：[1]广东省梅州市人民医院新生儿科,广东梅州514031

出　　处：《中国医药指南》2012年第2期12-13,共2页Guide of China Medicine

摘　　要：目的探讨肺表面活性物质治疗新生儿肺透明膜病的临床价值。方法随机性的抽取了我院2009年6月至2010年6月收治的48例肺透明膜病患儿,分为研究组和对照组各24例。研究组在出生后1d内使用肺表面活性物质来治疗,对照组不使用。比较X线、并发症和呼吸时间,评测肺表面活性物质疗效。结果研究组和对照组在X线、并发症和呼吸时间等有明显差异,卡方检验P<0.05。结论肺表面活性物质在治疗新生儿肺透明膜病上有较好的疗效,能减少并发症的发生,还能减少新生儿病死率。Objective To observe the efficacy of the application to the premature children,low birth weight children with hyaline membrane disease by applying pulmonary surfactant（PS）.Methods Select 48 cases of newborns were randomly divided into real risks group and control group in 2009 to 2010,and each group of 24 cases.In the group within 1d after lung surface active substances used,no application in lung,through the surface active material after 1d X of diagnosis and on time,the ventilator complications of comparative analysis,evaluation PS HMD prevention and treatment.Results Two groups in the ventilator number,number and mortality has significant difference（P〈0.05）.Conclusion PS applied to premature newborns can positively prevent and reduce the complications occurred the HMD premature,reduce newborns of mortality.

关 键 词：肺表面活性物质 肺透明膜病 新生儿 

分 类 号：R722.1[医药卫生—儿科]